Search

Author/Creator Wu, Ka Lung

1. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B‐cell lymphoma. (23rd August 2013)

Authors:
Coiffier, Bertrand; Radford, John; Bosly, André; Martinelli, Giovanni; Barca, Gabriela; Davies, Andrew; Decaudin, Didier; Gallop‐Evans, Eve; Padmanabhan‐Iyer, Swaminathan; Van, Koen; Wu, Ka Lung; Gupta, Ira V.; Lin, Thomas S.; Goldstein, Nancy; Jewell, Roxanne C.; Winter, Paul; Lisby, Steen
Journal:
British journal of haematology
Issue:
Volume 163:Number 3(2013:Nov.)
Page Start:
334
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Issue 6 (June 2020)

Authors:
Cavo, Michele; Gay, Francesca; Beksac, Meral; Pantani, Lucia; Petrucci, Maria Teresa; Dimopoulos, Meletios A; Dozza, Luca; van der Holt, Bronno; Zweegman, Sonja; Oliva, Stefania; van der Velden, Vincent H J; Zamagni, Elena; Palumbo, Giuseppe A; Patriarca, Francesca; Montefusco, Vittorio; Galli, M...
Journal:
Lancet
Issue:
Volume 7:Issue 6(2020)
Page Start:
e456
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Issue 6 (June 2020)

Authors:
Cavo, Michele; Gay, Francesca; Beksac, Meral; Pantani, Lucia; Petrucci, Maria Teresa; Dimopoulos, Meletios A; Dozza, Luca; van der Holt, Bronno; Zweegman, Sonja; Oliva, Stefania; van der Velden, Vincent H J; Zamagni, Elena; Palumbo, Giuseppe A; Patriarca, Francesca; Montefusco, Vittorio; Galli, M...
Journal:
Lancet
Issue:
Volume 7:Issue 6(2020)
Page Start:
e456
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Issue 6 (June 2021)

Authors:
Dimopoulos, Meletios A; Terpos, Evangelos; Boccadoro, Mario; Delimpasi, Sosana; Beksac, Meral; Katodritou, Eirini; Moreau, Philippe; Baldini, Luca; Symeonidis, Argiris; Bila, Jelena; Oriol, Albert; Mateos, Maria-Victoria; Einsele, Hermann; Orfanidis, Ioannis; Ahmadi, Tahamtan; Ukropec, Jon; Kampf...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 6(2021)
Page Start:
801
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians. (September 2013)

Authors:
Caers, Jo; Vekemans, Marie-Christiane; Bries, Greet; Beel, Karolien; Delrieu, Vanessa; Deweweire, Anne; Demuynck, Hilde; De Prijck, Bernard; De Samblanx, Hadewijch; Kentos, Alain; Meuleman, Nathalie; Mineur, Philippe; Offner, Fritz; Vande Broek, Isabelle; Van Droogenbroeck, Jan; Vande Velde, Ann;...
Journal:
Annals of medicine
Issue:
Volume 45:Number 5/6(2013)
Page Start:
413
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. Issue 8 (August 2019)

Authors:
Morschhauser, Franck; Le Gouill, Steven; Feugier, Pierre; Bailly, Sarah; Nicolas-Virelizier, Emmanuelle; Bijou, Fontanet; Salles, Gilles A; Tilly, Hervé; Fruchart, Christophe; Van Eygen, Koen; Snauwaert, Sylvia; Bonnet, Christophe; Haioun, Corinne; Thieblemont, Catherine; Bouabdallah, Reda; Wu, K...
Journal:
Lancet
Issue:
Volume 6:Issue 8(2019)
Page Start:
e429
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. Issue 8 (3rd August 2017)

Authors:
Vogl, Dan T.; Martin, Thomas G.; Vij, Ravi; Hari, Parameswaran; Mikhael, Joseph R.; Siegel, David; Wu, Ka Lung; Delforge, Michel; Gasparetto, Cristina
Journal:
Leukemia & lymphoma
Issue:
Volume 58:Issue 8(2017)
Page Start:
1872
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia. Issue 10 (3rd October 2017)

Authors:
Vojdeman, Fie J.; Herman, Sarah E. M.; Kirkby, Nikolai; Wiestner, Adrian; van t' Veer, Mars B.; Tjønnfjord, Geir E.; Itälä-Remes, Maija A.; Kimby, Eva; Farooqui, Mohammed Z.; Polliack, Aaron; Wu, Ka Lung; Doorduijn, Jeanette K.; Alemayehu, Wendimagegn G.; Wittebol, Shulamiet; Kozak, Tomas; Walews...
Journal:
Leukemia & lymphoma
Issue:
Volume 58:Issue 10(2017)
Page Start:
2356
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗